Evidence map›Paper›PMID 37419244›Full record

ArticleThe Journal of molecular diagnostics : JMD2023

Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid Tumors.

Harrison K Tsai, Tasos Gogakos, Va Lip, Jonathan M Tsai, Yen-Der Li, Adam S Fisch, Jonathan Weiss, Weiping Yang, Leslie Grimmett, Daniel DiToro and 11 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of molecular diagnostics : JMD, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. A novelBlood science (Baltimore, Md.) · 2026
    Article
  2. Strategies for identifyingHaematologica · 2026
    Article
  3. Biomedicines · 2024
    Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 4 institutions in 2 countries.

Harrison K TsaiDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: harrison.tsai@childrens.harvard.edu.
Tasos GogakosDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Va LipDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Jonathan M TsaiDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Yen-Der LiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Adam S FischDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Jonathan WeissDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Weiping YangDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Leslie GrimmettDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Daniel DiToroDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Eva J SchaeferDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
R Coleman LindsleyDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
Thai Hoa TranDivision of Pediatric Hematology-Oncology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada; Immune Diseases and Cancers Axis, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
Maxime CaronImmune Diseases and Cancers Axis, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
Sylvie LangloisImmune Diseases and Cancers Axis, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
Daniel SinnettDivision of Pediatric Hematology-Oncology, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada; Immune Diseases and Cancers Axis, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Quebec, Canada.
Yana PikmanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Valentina NardiDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
Annette S KimDepartment of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.
Lewis B SilvermanDepartment of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts; Division of Hematology/Oncology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
Marian H HarrisDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. Electronic address: marian.harris@childrens.harvard.edu.
Boston Children's Hospital · USHarvard University · USBrigham and Women's Hospital · USCentre Hospitalier Universitaire Sainte-Justine · CA

Funding

Targeting SYK Kinase in AMLP50CA206963 · NCI · DANA-FARBER CANCER INST · PI GRAUBERT, TIMOTHY A · 2017 to 2021
$10.6M
Targeting mitochondrial one carbon folate metabolism for novel T-cell acute lymphoblastic leukemia therapyK08CA222684 · NCI · DANA-FARBER CANCER INST · PI PIKMAN, YANA · 2018 to 2022
$886k
NCI NIH HHS K08 CA222684NCI NIH HHS P50 CA206963
6 · The paper itself

Abstract

Recognition of aberrant gene isoforms due to DNA events can impact risk stratification and molecular classification of hematolymphoid tumors. In myelodysplastic syndromes, KMT2A partial tandem duplication (PTD) was one of the top adverse predictors in the International Prognostic Scoring System-Molecular study. In B-cell acute lymphoblastic leukemia (B-ALL), ERG isoforms have been proposed as markers of favorable-risk DUX4 rearrangements, whereas deletion-mediated IKZF1 isoforms are associated with adverse prognosis and have been extended to the high-risk IKZF1

Indexed as

NeoplasmsPrecursor B-Cell Lymphoblastic Leukemia-LymphomaGenomicsHumansProtein IsoformsSequence Analysis, RNAProtein Isoforms

Identifiers

PMID37419244
PMCPMC10488324
OpenAlexW4383164304

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.